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Lung cancer kills both men and women in the United States more
than any other type of cancers, causing an estimated 156 900
deaths in 2000 and accounting for 28% of all cancer deaths, in
spite of improved therapy available and nationwide anti-smoking
campaign (Cancer Facts and Figures – 2000, American Cancer
Society). Extensive studies have shown that the development of
lung cancer, like many other cancers, is a multistep process which
takes several years and proceeds presumably through a series of
molecular events leading to an accumulation of genetic variation
including mutational, chromosomal and epigenetic changes
(Harris, 1991; Sozzi et al, 1995; Stanley, 1995). In this paradigm,
one major pathway to lung malignancy involves structural alter-
ations of cancer-related genes, including activation of dominant
oncogenes and inactivation of tumour suppressor genes (Barbacid,
1987; Bishop, 1991; Hollstein, 1991; Gazdar, 1994; Stanley, 1995) 
The K-ras oncogene has been frequently found in mutated form
in lung tumours and cell lines; K-ras mutations are often associ-
ated with the development of lung cancer. This gene codes for a
21-kd protein (ras), which is related to the G proteins which bind
guanine nucleotides with high affinity and are located at the inner
surface of the cell membrane. These proteins have an important
role in the signal transduction pathway (Barbacid, 1987; Bishop,
1991; Khosravi-Far and Der, 1994). Activation of the ras genes
occurs with specific point mutations at only a very few codons
including codons 12, 13 or 61, with codon 12 being mutated in
more than 90% of K-ras mutations identified in lung tumours
(Suzuki et al, 1990; Sugio et al, 1992; Rodenhuis and Slebos,
1992; Husgafvel-Pursiainen et al, 1993; Rosell et al, 1996;
Keohavong et al, 1996). These mutations induce structural
changes within the ras proteins leading to an ‘activated’ GTP-
bound conformation. 
Lung cancer has been grouped into 4 major histologic types,
including adenocarcinoma, squamous cell carcinoma, large cell
carcinoma, and small cell lung carcinoma (SCLC). The first 3
types are termed collectively non-small cell lung carcinoma
(NSCLC) and have different clinical features from SCLC (Minna
et al, 1989). K-ras mutations occur in 15% to 50% of adenocarci-
noma and large cell undifferentiated carcinoma of the lung.
Particularly, they have been more frequently found in tumours
from smokers (21–35%) than in those from nonsmokers (5–7%),
suggesting their formation may be associated with tobacco smoke
exposure. They have also been found, but at a lower frequency, in
other forms of pulmonary neoplasia, including squamous cell
carcinoma (Suzuki et al, 1990; Sugio et al, 1992; Rodenhuis and
Slebos 1992; Husgafvel-Pursiainen, 1993; Rosell et al, 1996;
Keohavong et al, 1996, 1997a). 
Although K-ras mutations have been frequently found in lung
tumours, the timing of their occurrence in the multistep process of
lung carcinogenesis remains poorly understood. Such studies used
tissue specimens removed at biopsy or resection (Sugio et al,
1992; Westra et al, 1993; Clements et al, 1995; Yakubovskaya et
al, 1995; Urban et al, 1996; Keohavong et al, 1997b; Urban et al,
2000), and cell samples microdissected from embedded lung
tissue sections (Sugio et al, 1994; Westra et al, 1996). Taken
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relatively late in lung cancer development (Sugio et al, 1994;
Yakubovskaya et al, 1995; Urban et al, 1996), while other studies
indicate that they could represent early events in this process (Li 
et al, 1994; Clements et al, 1995; Keohavong et al, 1997b; Urban 
et al, 2000). 
We have previously applied a sensitive method to analyse and
compare K-ras mutations in lung tumour and matched tumour-
adjacent histologically normal tissues (Keohavong et al, 1997).
We have reported that histologically normal tissues taken from
outside K-ras-mutated lung tumours contained a low fraction of
the mutational genotype identical to those found in the corre-
sponding tumour in 4 of 8 lung cancer patients. However, the fact
that such a study used tissue samples that each contained several
hundreds cells, there were some concerns that the low fraction
mutations detected in the histologically normal tissues might have
originated from a contamination with very few tumour cells or
mutated DNA diffusing from necrotic tumour cells in surrounding
tissues, although we took all precautions to avoid or at least mini-
mize such a possibility (Keohavong et al, 1997b). In this study, we
applied a laser capture microdissection technique to histopatholog-
ically review and precisely sample, under direct microscope visu-
alization, a few cells from various areas of paraffin-embedded
lung tissue sections, including histologically normal tissue and
matched tumour tissue, obtained from 48 cases of lung cancer
patients. We analysed K-ras mutations in each cell sample using
polymerase chain reaction and denaturing gradient gel elec-
trophoresis. The results demonstrate that K-ras mutations are
present in histologically normal tissue surrounding lung tumour in
about 15.8% (6 of 38) of patients with lung adenocarcinoma. We
compared these results with those reported previously by us and
others and discussed them in relation to the role of K-ras muta-
tions in lung carcinogenesis and as potential surrogate biomarkers
for lung cancer. 
MATERIALS AND METHODS 
Patients and tissue specimens 
Pulmonary lobectomy specimens were obtained from 48 patients
with lung cancer, including 38 adenocarcinoma and 10 squamous
cell carcinoma. The demographic and clinical information is
shown in Table 1. These specimens were formalin-fixed and
paraffin- embedded and stored at the University of Pittsburgh
Medical Center between 1990 and 1999. The diagnosis of lung
adenocarcinoma and squamous cell carcinoma was confirmed,
using established morphologic criteria. For DNA analysis, 5 mm
histologic sections were prepared from multiple paraffin blocks
representative of tumour and those representative of matched
histologically normal lung tissues (located between 2.0 cm and 5.0
cm from the tumour edge). These normal tissues corresponded to
either bronchial or bronchiolar pseudostratified columnar epithe-
lial tissues that matched tumours (adenocarcinoma or squamous
cell carcinoma) of a bronchial origin, or alveolar walls that
matched tumors (adenocarcinoma or bronchoalveolar type) of an
alveolar origin. All tissue sections were individually deparaf-
finized in xylene and then in ethanol, rinsed with water, and air-
dried. All slides were stained with hematoxylin and eosin and
reviewed to confirm the presence of histologically normal tissue
and/or tumour. The microdissection was performed by a trained
pathologist using a laser capture microdissection microscope
(PixCell II LCM System, Arcturus Engineering, Mountain View,
CA). With the aid of this new technique, individual cells within
areas of interest of a tissue section were isolated (Emmert-Buck 
et al, 1996). Areas of tumour tissue and histologically normal
tissue were prepared and microdissected separately to avoid 
any possible cross-contamination between tissues. Samples of
100–200 histologically normal cells or malignant cells were ‘laser-
captured’ on separate ‘Caps’ built to fit a 0.5 ml microcentrifuge
tube (Acturus Engineering, Mountain View, CA). Each cell sample
was considered to be 100% ‘homogeneously’ normal-appearing or
malignant, as determined by a careful microscopic visualization of
the cells captured on each Cap. 
DNA extraction and K-ras codon 12 mutation analysis 
The captured cells were lysed by adding directly on each Cap 20
ml of lysis solution (40 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.5%
Tween-20, and 0.5 mg ml–1 proteinase K) (Sugio et al, 1994). The
Cap was enclosed into a 0.5 ml microcentrifuge tube (in an upside-
down position) and incubated at room temperature for 48 hours
with occasional gentle shaking. The resulting cell lysate was
recovered in the tube by a quick and gentle spinning in a micro-
centrifuge then heated at 95°C for 5 minutes to inactivate the
proteinase K. Half (10 ml) of each cell lysate was used as template
for a first round of PCR to amplify a 75-bp genomic fragment
containing the 5¢ half of exon 1 of the K-ras gene and adjacent
flanking intron sequence. PCR was carried out in a final 50 ml
reaction mixture containing 10 mM Tris-HCl, pH 8.3, 1.5 mM
MgCl2, 50 mM KCl, 100 mM each dNTP, 0.5 mM each primer and
2.5 units of Gold AmpliTaq DNA polymerase (Perkin Elmer, CT).
The mixture was heated at 95°C for 9 minutes then subjected to 15
cycles (94°C/1 minute, 53°C/1 minute, 72°C/1 minute), using the
primers KI1-1 (sense): 5¢- TATTATAAGGCCTGCTGAAA-3¢ and
PKB (antisense): 5¢- AGGCACTCTTGCCTACGGCA-3¢. For the
second round of PCR, 2 ml of the PCR products from the first
round were diluted into a final 25 ml reaction mixture containing
the same buffer composition as above except that 0.25 ml of [a-
32P]-dATP (3000 Ci/mmol, New England Nuclear, Boston, MA)
was added and primer KI1-1 was replaced by primer PKGC: 5¢-
GCCGCCTGCAGCCCGCGCCCCCCGTGCCCCCGCCCCGC-
CGCCGGCCCGGCGCCTATAAGGCCTGCTGAAAATG-3¢.
The mixture was heated at 95°C for 9 minutes then subjected to 35
PCR cycles (94°C/1 minute, 60°C/1 minute, 72°C/1 minute). The
resulting PCR products were separated by gel electrophoresis and
autoradiographed. Band containing the expected-size 126-bp frag-
ment was excised from the gel. DNA was eluted from the gel slice
and analysed by DGGE (Bio-Rad, CA) under the conditions
described previously (Keohavong et al, 1997b). Mutant alleles
were isolated from the denaturing gradient gel and further charac-
terized by sequencing. This method allows us to clearly detect a K-
ras mutant allele present at a mutant fraction of 5% (1 mutant
allele among 20 wild-type alleles) (Keohavong et al, 1997b). This
level of sensitivity should be sufficient to identify K-ras mutations
in DNA samples from an equivalent 50–100 original cells. In the
cases where mutant alleles appeared ambiguous by using the
above PCR+DGGE method, a more sensitive version of this
method which has a detection limit of 10–3–10–4 (one mutant allele
in 103–104 wild-type allele) was used. This method requires an
additional step for mutant allele enrichment involving a prior treat-
ment of the 126-bp amplified fragment with Ban I restriction
enzyme which cleaves fragments with a non-mutated K-ras codon
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by DGGE as described previously (Keohavong et al, 1997b). 
RESULTS 
Lung tissue sampling and microdissection 
Figure 1 shows a representative example of a target-site sampling
from a case of lung adenocarcinoma. The use of a laser capture
microscopy allowed an accurate morphologic analysis and precise
sampling of cells from areas of interest in paraffin-embedded
tissue sections. Histologically normal cells were individually
resected by laser capture from the tissue area located between 2 cm
and 5 cm from the edge of the tumour area. Between 100 and 200
cells were captured on each Cap after a careful histologic exami-
nation and determination of their benign morphology. All cells
appeared homogeneously normal-looking and there were no
tumour cells present. Paraffin-embedded tissue blocks representa-
tive of tumour tissue were topographically sampled in a similar
manner. The cells captured from the tumour tissue also all
appeared malignant histologically. After microdissection, each
captured cell sample was compared to the matched tissue section
prior to and after microdissection to confirm the accuracy of target
selection (see Figure 1A–D). Using this approach, we prepared 38
cell samples from histologically normal tissue and 38 cell samples
from matched malignant tissue from paraffin-embedded lung
tissue sections selected from 38 patients with lung adenocarci-
noma. We also prepared cell samples from histologically normal
tissue, matched metaplasia and tumour tissue from paraffin-
embedded tissue sections obtained from 10 patients with lung
squamous cell carcinoma. 
Mutation analysis 
Molecular analysis of the above cell samples using the
PCR+DGGE method yielded 10 lung cancer cases showing K-ras
mutant alleles in tumour cells and/or paired histologically normal
cells, all of which corresponded to lung adenocarcinoma (26.3% or
10 of 38 cases). Figure 2 shows an example of DGGE separation
of K-ras mutant alleles from the wild-type allele for 6 of the 10 
K-ras mutant-positive cases. The mutant alleles were isolated
from the gel and the nature of the mutations was determined by
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Figure 1 An example of tissue site sampling from a formalin-fixed and paraffin-embedded tissue section from one case of lung adenocarcinoma (see patient 4
in Table 1) by using a laser capture microdissection microscope (magnification ´ 100). The figure shows a tissue section obtained from a block representative of
a histologically normal lung tissue pre- (A) and post- (B) topographic microdissection of normal-appearing cells from an area of interest of the tissue section.
The cells were ‘captured’ on a Cap (C) and reviewed further for cell population homogeneity and then treated with proteinase K. (D) shows the same cell
sample after treatment with proteinase K, with the cellular content being totally lysed. Under the lysis conditions shown in Materials and Methods, between 95%
and 100% of the captured cells were completely lysed sequencing. No mutants were identified in any of the cell samples
corresponding to tumour tissue or paired histologically normal
tissue obtained from the 10 cases of squamous cell carcinoma
(data not shown). These results are in line with previous studies
showing that K-ras mutations were frequently identified in lung
adenocarcinoma but were rarely so in lung squamous cell carci-
noma (Rodenhuis and Slebos, 1992; Husgafvel-Pursiainen et al,
1993; Keohavong et al, 1996). As shown in Figure 2, the 2 control
samples of known normal tissues (C1 and C2) revealed only the
K-ras codon 12 wild-type homoduplex (wt). Compared with the
controls, patients 3 and 5 showed each a mutant pattern in the
tumour tissue but not in the paired histologically normal tissue.
These patients harboured each a GGT to TGT mutation in their
lung tumour tissue. In addition, in patient 5, the wild-type allele
appeared only as a small fraction of the mutant allele in this
tumour sample (T). This observation may indicate that some
tumour cell in this sample may have lost 1 allele of K-ras gene
while containing a mutation in the remaining allele. This loss of
the wild-type allele appeared to occur at a specific area of the
tumour tissue because further analysis of tumour cells taken from
2 separate sites of tumour tissue from this patient showed not only
the TGT mutation but also the wild-type allele at a fraction higher
than the TGT mutant allele in both samples (data not shown).
Nevertheless, the presence of a loss of 1 allele and a mutation in
the other allele of the K-ras gene has not been reported previously.
It may be that the deletion of the wild-type allele occurred as a
secondary event that accumulated during the progression of cells
with already a K-ras mutated gene in one allele into tumour.
Patients 2, 4 and 6 each harboured a genotypically identical muta-
tion in both the tumour tissue and the paired histologically normal
tissue, corresponding to a GGT to TTT, a GGT to GTT, and GGT
to TGT, respectively. Patient 1 showed 4 mutant/wild-type
heteroduplexes in the histologically normal tissue (N), which were
found to correspond to 2 different mutations, a GTT to ATT in
codon 9, and a GCT to ACT in codon 11, of the K-ras gene. This
patient also showed two mutant/wild-type heteroduplexes in the
matched tumour tissue (T), which corresponded to a GGT to GAT
mutation in codon 12 of the K-ras gene. 
Multiple site analysis of K-ras mutations 
In order to investigate in more detail the topographic distribution
of mutations in each lung tumour tissue and histologically normal
tissue, all 10 K-ras mutation-positive adenocarcinomas as well as
3 K-ras mutation-negative adenocarcinomas were re-examined
further for K-ras mutations. Toward this end, between 3 and 5
additional successive tissue sections were prepared from original
tissue blocks representing tumour-surrounding histologically
normal tissue as well as those representing tumour tissue for each
cancer case. Table 1 summarizes the final results of K-ras muta-
tions identified at multiple sites in both the histologically normal
tissue and the matched tumour tissue for the 10 cases of K-ras
mutation-positive lung adenocarcinomas. The cell samples
obtained from the tumour tissue and histologically normal tissue
for the 3 selected K-ras mutation-negative patients were all found
to be negative for K-ras mutations (data not shown), confirming
the results of the first experiment. 4 of the 10 K-ras mutation-
positive cases (Patients 3, 5, 7 and 8) contained each a mutation 
(a GGT to TGT) in only the tumour tissue. This mutation was
present in all malignant cell samples taken from 3 different areas
of the tumour tissue from each of these patients. Patients 2 and 6
each contained a genotypically identical mutation (a GGT to TTT
and GGT to TGT, respectively) in both the tumour tissue and
matched histologically normal tissue. These mutations were
present in all cell samples taken from 3 different tissue blocks
representative of the normal-appearing tissue and those represen-
tative of the matched tumour tissue obtained from these patients,
in agreement with the results of the first experiment shown in
Figure 2 for these patients. Likewise, multiple site analysis helped
confirm that Patient 4 contained a genotypically identical muta-
tion, a GGT to GTT, in both the tumour tissue and histologically
normal tissue. In addition, as shown in Figure 3, a second muta-
tion, a GGT to AGT, was detected in the histologically normal
tissue. However, while the GGT to GTT mutation was found in all
tissue blocks representative of the histologically tissue (see lanes
N1, N2 and N3 and n1 n2, and n3), as well as those representative
of the tumour tissue (see T1, T2 and T3), the GGT to AGT muta-
tion was found in only cell samples taken from one specific area of
the histologically normal tissue (see lanes N1 and n1). This tissue
area was defined at the margin of resection located 5 cm from the
edge of the tumour. In the remaining 3 patients (Patients 1, 9 and
10; Table 1), the mutations were identified at a low fraction as
shown by the fact they were identified only in 1 or 2 of the total 6
cell samples taken from the histologically normal tissue and/or the
tumour tissue and by only using a more sensitive version of the
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Figure 2 DGGE analysis of K-ras mutations, K-ras gene exon 1 is amplified
from cellular DNA isolated from each cell sample microdissected from
histologically normal (N) and tumour (T) areas of a selected lung tissue
section as shown in Figure 1. The amplified DNA is analysed by DGGE to
separate any K-ras mutant allele that may be present in each cell sample
from the wild type allele. The figure shows sequence patterns of K-ras mutant
alleles for 6 of 10 lung adenocarcinoma that were found to be positive for K-
ras mutation in the tumour tissue and/or the histologically normal tissue. The
wild-type allele was present in excess over mutant allele(s) in each DNA
sample, except for the tumour DNA sample in patient 5, and was detected as
a homoduplex fragment (wt). The presence of a mutant allele was detected
as 3 additional fragments, including a mutant homoduplex and the 2
respective mutant/wild-type heteroduplexes that separated from the wild-type
fragment in lower denaturant concentrations from the bottom to the top of the
gel, respectively. In patient 1, the histologically normal DNA sample showed
4 mutant/wild-type heteroduplexes that corresponded to the presence of 2
different mutant alleles (see patient 1 in Table 1). Lanes C show the
sequence patterns of negative control DNA samples corresponding to a
known K-ras mutation-negative benign lung tissue (C1) and infant normal
intestine tissue (C2). The histologically normal tissue sample (N) in patient 6
contained several faint heteroduplex bands. Further experiments showed that
only the 2 heteroduplexes identical to those appearing in the matched tumour
sample (T) were repeatedly detected. Therefore, the presence of the other
heteroduplexes in the histologically normal tissue sample (N) was
presumably due to experimental variation PCR + DGGE method (see Materials and Methods). Patient 1
contained 2 mutations in codon 12 (a GGT to GAT and GGT to
AGT) in tumour tissue and 2 mutations, 1 in codon 9 (a GTT to
ATT) and 1 in codon 11 (a GCT to ACT), in histologically normal
tissue. These mutations were identified each in only 1 or 2 of the 6
samples taken from either the tumour tissue or the histologically
normal tissue. In Patient 9, 2 mutations (a GGT to GAT and GGT
to AGT) were found in histologically normal tissue and 1 mutation
(a GGT to AGT) was found in tumour tissue. In Patient 10, 1 mutation
(a GGT to AGT) was found in 2 of 6 samples taken from the histo-
logically normal tissue and in none of 6 malignant cell samples. 
DISCUSSION 
Although K-ras mutations have been frequently found in lung
tumours and tumour cell lines and implicated in the development
of lung cancer, the timing of these mutations in lung carcinogen-
esis remains poorly understood. There have been several but
conflicting reports on whether or not K-ras mutations are present
in non-neoplastic or normal-appearing lung tissues, which, in the
affirmative, would indicate that they occur early during lung
cancer development and can provide an early lung cancer detec-
tion marker. 
We applied a laser capture microdissection microscope to
morphologically review and sample cells at multiple sites from
both lung tumour tissue and histologically normal tissue adjacent
to as well as those distant from the tumour. Our results, based on
independent experiments using successive lung tissue sections
from multiple tissue blocks, demonstrated that K-ras mutations
were present in histologically normal tissue in 6 of 10 (60%) K-ras
mutation-positive lung adenocarcinomas, or 6 of all 38 (15.8%)
lung adenocarcinomas examined. Therefore, K-ras mutations 
are relatively frequent in histologically normal lung tissue
surrounding malignant tissue in lung adenocarcinomas. These
mutations can be grouped into high fraction mutations and low
fraction mutations in tumour and/or histologically normal tissue.
Low fraction K-ras mutations have been previously reported in
lung tumour DNA by us and others (Mills et al, 1995; Keohavong
et al, 1997a). They were frequently identified in tumour tissue 
as well as in histologically normal tissue and metastasis
(Yakubovskaya et al, 1995). Our present study showed that muta-
tions in patients 1, 9 and 10 were detected in only some cell
samples taken from malignant tissue and/or matched histologically
normal tissue, suggesting that they were not initiating or early events
in lung carcinogenesis but rather secondary events accumulating in
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Table 1 Summary of K-ras mutations in lung tissue sections from 10 cases of lung adenocarcinomaa
Mutations 
Patient no. Gender Age Normal tissue  Tumour tissue Amino acid change 
1 M 62 cod.9 (GTT to ATT) Val to Ile 
cod.11 (GCT to ACT) Ala to Thr 
GAT Asp 
AGT Ser 
2 F 48 TTT TTT Phe 
3 M 66 none TGT Cys 
4 M 53 GTT GTT Val 
AGT Ser 
5 M 60 none TGT Cys 
6 M 74 TGT TGT Cys 
7 M 53 none TGT Cys 
8 M 72 none TGT Cys 
9 M 66 GAT Asp 
AGT AGT Ser 
10 F 72 AGT none Ser 
aExcept for the 2 mutations found in histologically normal tissues in patient 1, all mutations shown involved codon 12
of the K-ras gene.
wt
Patient 4 C1 C2 T1 T2 T3 N1 N2 N3 n1 n2 n3 c1 c2
Figure 3 An example of DGGE analysis of K-ras mutations at multiple sites
of lung tissue sections for patient 4 shown in Table 1. The figure shows the
GGT to GTT mutant sequence pattern in cells sampled at 3 regions of the
tumour tissue (T1, T2, T3) and 3 regions of the histologically normal tissue
(N1, N2, N3) corresponding to patient 4. The histologically normal cells were
sampled at 5 cm (N1 and N2) and 2 cm (N3) from the edge of the tumour.
Lanes C1 and C2 contained DNA with non-mutated K-ras gene
corresponding to benign lung tissue and infant intestinal tissue, respectively.
Shown in lanes n1, n2, n3, and c1 and c2, are the same DNA from N1, N2,
N3, and C1 and C2, that had been first subjected to BanI restriction enzyme
digestion to eliminate any non-K-ras codon 12 mutant allele, including the
wild-type allele (wt), and thereby to enrich for K-ras codon 12 mutant alleles,
then analysed by DGGE (Keohavong et al, 1997). The positions of the mutant
homoduplexes (second fragment from wt) and the 2 respective mutant/wild-
type heteroduplexes (third and fourth fragments from wt) were indicated by
arrows for the GGT to GTT mutation in lanes T1–T3, and by arrowheads for
the GGT to AGT mutation in lanes N1–N3 and n1. After mutant allele-
enrichment by BanI digestion, the GGT to AGT mutant pattern in lane N1
appeared more clearly visible in lane n1. As expected, control DNA shown in
lanes c1 and c2 did not contain any K-ras codon 12 mutant allele subclones during tumour progression or as a result of continued
exposure to tobacco smoke (Mills et al, 1995; Yakubovskaya et al,
1995; Keohavong et al, 1997a). The GTT to ATT mutation (codon
9) and GCT to ACT mutation (codon 11) found in patient 1 had
not been reported previously and their biological significance in
lung carcinogenesis is not known. Among the lung adenocarci-
nomas with high fraction mutations, 2 observations can be made.
First, these mutations can be found in only the tumour tissue and
not in the matched histologically normal tissue (Patients 3, 5, 7
and 8). The fact that they were detected at multiple sites in lung
tumour tissue suggests that they may represent events occurring
early in small precursor lesions before tumour progression.
Secondly, some K-ras mutations are found not only in the tumour
tissue but also, at a mutant fraction generally lower than that
detected in the tumour tissue, in histologically normal tissues adja-
cent to as well as those distant from the tumour (Patients 2, 4 and
6). These results confirmed our previous study showing that geno-
typically identical K-ras mutations were detected in both the
tumour tissue and, at a lower mutant fraction, in tumour-adjacent
normal-appearing tissue in 4 of 8 cases of lung adenocarcinoma
(Keohavong et al, 1997). These mutations may represent early
events, perhaps initiating events, in the development of these
tumours. Furthermore, Patient 4 provides an intriguing example
since only 1 mutation, a GGT to GTT, is present in the tumour
tissue, but 2 mutations, a GGT to GTT and GGT to AGT, are
present in the matched histologically normal tissue. In addition,
while the GTT mutation was detected in all samples taken from 6
different sites of the histologically normal tissue, the GGT to AGT
mutation was detected in only cell samples taken from a defined
area of the normal-appearing tissue distant from the tumour. This
observation is compatible with the existence of 2 overlapping
fields with each a different mutated K-ras gene, and the field with
the GTT mutation may contribute to the development of this
tumour (Slaughter et al, 1953; Strong et al, 1984). It is, however,
unclear why a field with a specific mutation would have a higher
ability to develop into a tumour than one with another mutation
type. Some studies suggested that the substitution of the wild-type
codon 12 amino acid (glycine) with certain amino acids, including
valine and arginine, in the H-ras gene may give rise to gene prod-
ucts with a more potent transforming ability than the wild-type or
other amino acids (Seeburgh et al, 1984; Der et al, 1986). It will
require an expanded study involving a larger number of lung
cancer patients to determine whether our explanation for the
observation in patient 4 can be supported. 
K-ras mutations were detected in histologically normal mucosal
tissues adjacent to or distant from colorectal carcinoma (Pretlow 
et al, 1991; Minamoto et al, 1995; Zhu et al, 1997). They have
been also suggested to be preneoplastic events in pancreatic cancer
(Yanagisawa et al, 1993; Berthelemy et al, 1995; Brentall et al,
1995; Tada et al, 1996; Wilentz et al, 1998). However, in lung
cancer, there have been conflicting reports on K-ras mutations in
non-neoplastic tissues. On the one hand, Santos et al (1984) inves-
tigated K-ras codon 12 mutation in lung tissues obtained from a
patient with squamous cell carcinoma of the lung and reported that
the mutation detected in lung carcinoma was absent from the
normal bronchial and parenchymal tissues of that patient. The
authors suggested that malignant activation of K-ras oncogene
may be specifically associated with the development of a human
neoplasm. Sugio et al (1994) reported that K-ras mutations
were absent in metaplasia and normal-appearing cells of the lung
and were infrequent in dysplastic lesions, suggesting that these
mutations are relatively late events in the pathogenesis of lung
cancer. Likewise, Urban et al (1996) did not detect any K-ras
mutation in non-neoplastic peripheral bronchial or parenchymal
tissues associated with lung tumours. Finally, Yakubovskaya et al
(1995) detected K-ras mutations in 60% of normal-appearing lung
tissue samples, 63% of tissue samples from tumour tissue, and
80% of samples of metastasis obtained from patients with non-
small cell lung cancer. However, the fact these mutations were
present at a low fraction suggests that they did not contribute to the
development of lung cancer. On the other hand, the results of these
studies are not in agreement with other published studies. For
instance, K-ras mutations were identified in atypical alveolar
hyperplasia (AAH), a potential precursor from which lung adeno-
carcinoma arises (Westra et al, 1996). In another study, Clements
et al (1995) analysed bronchoscopy specimens obtained from lung
cancer patients and showed that K-ras mutations were found in
both malignant and nonmalignant tissues in 22.7% (5 of 22) of 
the patients and in only nonmalignant tissue in 9.1% (2 of 22) of the
patients. Finally, a recent study by Urban et al (2000) showed that
K-ras mutations were detected in both lung tumour and bronchial
carina tissue in 21% (4 of 19) of the patients, while being present
only in the bronchial carina but not in the tumour in 11% (2 of 19)
of the patients. These latter studies and our present study showed
that K-ras mutations can be frequently found in non-neoplastic
lung tissues, including histologically normal tissues. 
Questions remain about the usefulness of K-ras mutations as an
early detection markers for lung cancer. Mutation in the K-ras
gene is a well-established example of the association between
environmental exposure (chiefly tobacco smoke) and human lung
cancer, since mutations in the K-ras gene are found almost exclu-
sively in lung tumours from smokers, while being rare in lung
tumours from non-smokers (Rodenhius and Slebos, 1992; Sugio 
et al, 1992; Suzuki et al, 1990; Husgafvel-Pursianen et al, 1993;
Keohavong et al, 1996; Rosell et al, 1996). In theory, these muta-
tions should be useful markers of exposure to carcinogens in
tobacco smoke, and their detection in high-risk individuals
without cancer would be an indication of damaged airway epithe-
lium. The presence of these mutations in airways of ex-smokers
might also be an indication of persistence of genetic damage in
‘condemned epithelium’. The technique of laser capture microdis-
section as described here could be applied to mucosal biopsies
taken by either white light or fluorescent bronchoscopy to deter-
mine if K-ras mutations are present in preneoplastic or histologi-
cally normal epithelium from the airways of individuals at high
risk for lung cancer. 
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